Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his abdomen after drinking water. It was just a fleeting moment; one he brushed ...

NEW YORK & TOKYO - Pfizer Inc. (NYSE: NYSE:PFE) and Astellas Pharma Inc. (TSE: TYO:4503) have announced updated results from the Phase 3 EV-302 clinical trial, which showed that the combination of ...

2024 — A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer ...

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

which include durvalumab and enfortumab vedotin combined with pembrolizumab, are presenting game-changing benefits to bladder cancer patients,” says Douglas. “The exceptional responses being ...

which include durvalumab and enfortumab vedotin combined with pembrolizumab, are presenting game-changing benefits to bladder cancer patients,” says Douglas. “The exceptional responses being ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

MRI scanning and biopsy could reduce delays in the correct treatment for bladder cancer by more than six weeks Date: January 15, 2025 Source: University of Birmingham Summary: Patients with a ...

PADCEV is a prescription medicine that may be used with pembrolizumab for adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter, or urethra) that has spread or cannot ...